PharmaPoint: Colorectal Cancer - Japan Drug Market Forecast and Analysis to 2023 that is driven by industry demands illuminated by new report

"The Report PharmaPoint: Colorectal Cancer - Japan Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

GlobalData has released its new PharmaPoint Country Evaluation report, PharmaPoint: Colorectal Cancer Japan Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Japan represents the second-largest market for CRC across the countries covered in this report. Japan is a major CRC market, due to the high incidence of the disease and high drug treatment rates. Increased sales of CRC therapies over the forecast period will be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies that provide further treatment options for patients in later-line settings, replacing cheaper generic chemotherapy only regimens.

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/237894

Scope

• Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in Japan from 2013-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the Japan CRC market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for CRC
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 10

2 Introduction 11

2.1 Catalyst 11

2.2 Related Reports 12

2.3 Upcoming Related Reports 13

3 Disease Overview 14

3.1 Etiology and Pathophysiology 14

3.1.1 Etiology 14

3.1.2 Pathophysiology 16

3.2 Clinical Staging 17

3.3 Symptoms 19

4 Disease Management 20

4.1 Diagnosis and Treatment Overview 20

4.1.1 Screening and Diagnosis 20

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 23

4.1.3 Clinical Practice 24

4.2 Japan 30

4.2.1 Screening and Diagnosis 32

4.2.2 Clinical Practice 32

5 Competitive Assessment 34

5.1 Overview 34

5.2 Product Profiles Major Brands 35

5.2.1 Avastin (Bevacizumab) 35

5.2.2 Erbitux (Cetuximab) 39

5.2.3 Vectibix (Panitumumab) 43

5.2.4 Stivarga (Regorafenib) 47

5.2.5 Zaltrap (Ziv-Aflibrcept) 51

5.2.6 Lonsurf (TAS-102) 54

5.2.7 TS-1 (Tegafur, Gimeracil, Oteracil) 58

5.2.8 Xeloda (Capecitabine) 61

6 Unmet Need and Opportunity 65

6.1 Overview 65

6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 66

6.2.1 Unmet Need 66

6.2.2 Gap Analysis 68

6.2.3 Opportunity 68

6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 70

6.3.1 Unmet Need 70

6.3.2 Gap Analysis 71

6.3.3 Opportunity 71

6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 72

6.4.1 Unmet Need 72

6.4.2 Gap Analysis 73

6.4.3 Opportunity 73

6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 74

6.5.1 Unmet Need 74

6.5.2 Gap Analysis 74

6.5.3 Opportunity 75

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

PharmaPoint Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023 illuminated by new report

"The Report PharmaPoint: Colorectal Cancer - 5EU Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

GlobalData has released its new PharmaPoint Country Evaluation report, PharmaPoint: Colorectal Cancer 5EU Drug Forecast and Market Analysis to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Growth of the French market is expected to be driven by increasing disease incident cases as the population ages, label extension of Stivarga as an adjuvant treatment for resected liver metastases patients, and the launch of expensive new therapies such as MGN-1703, a maintenance therapy for first-line patients responding to chemotherapy with or without biological agents. Germany has shifted towards a strict reference pricing system and has begun implementing price cuts, indicating that pharmaceutical companies can no longer count on the free pricing schemes previously in place in the German market. GlobalData believes that the government is likely to make similar moves in the future. As in the 5EU in general, cost effectiveness is a major priority for the Italian government and will be a major limitation on the pricing and uptake of new drugs during the forecast period. The Spanish government has been forced to institute severe cost-control measures due to economic policies stemming from the 2008 financial crisis. Growth in the UK is expected to be restricted by the NHS reimbursement watchdog, NICE. At present, no branded treatments have been given approval from NICE in the UK.

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/237893

Scope

• Overview of CRC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in 5EU from 2013-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the 5EU CRC market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for CRC
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2013-2023 in 5EU.

Table of Contents

1 Table of Contents 5

1.1 List of Tables 9

1.2 List of Figures 12

2 Introduction 13

2.1 Catalyst 13

2.2 Related Reports 14

2.3 Upcoming Related Reports 15

3 Disease Overview 16

3.1 Etiology and Pathophysiology 16

3.1.1 Etiology 16

3.1.2 Pathophysiology 18

3.2 Clinical Staging 19

3.3 Symptoms 20

4 Disease Management 22

4.1 Diagnosis and Treatment Overview 22

4.1.1 Screening and Diagnosis 22

4.1.2 Treatment Guidelines and Leading Prescribed Drugs 25

4.1.3 Clinical Practice 29

4.2 France 34

4.2.1 Screening and Diagnosis 36

4.2.2 Clinical Practice 36

4.3 Germany 38

4.3.1 Screening and Diagnosis 40

4.3.2 Clinical Practice 40

4.4 Italy 42

4.4.1 Screening and Diagnosis 44

4.4.2 Clinical Practice 44

4.5 Spain 46

4.5.1 Screening and Diagnosis 48

4.5.2 Clinical Practice 48

4.6 UK 50

4.6.1 Screening and Diagnosis 52

4.6.2 Clinical Practice 52

5 Competitive Assessment 55

5.1 Overview 55

5.2 Product Profiles Major Brands 56

5.2.1 Avastin (Bevacizumab) 56

5.2.2 Erbitux (Cetuximab) 61

5.2.3 Vectibix (Panitumumab) 65

5.2.4 Stivarga (Regorafenib) 68

5.2.5 Zaltrap (Ziv-Aflibrcept) 72

5.2.6 Lonsurf (TAS-102) 76

5.2.7 Xeloda (Capecitabine) 80

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Global PharmaPoint Asthma - Drug Forecast, Market Status, Opportunities and Analysis to 2023

"The Report PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

View Report At :http://www.marketresearchreports.biz/analysis/234591

Highlights

Key Questions Answered

• Asthma symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 5-10% of people with asthma, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the asthma market?
• The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. Will the late-stage drugs make a significant impact on the asthma market? What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market?
• The prevalence of environmental diseases, including asthma, is increasing worldwide, with an estimated 400 million people likely to suffer from asthma in 2025. How will epidemiological changes impact the growth of the future market?

Key Findings

• The main driver of the enormous expansion of the asthma market will be the uptake of novel targeted biologic agents and once-daily ICS and ICS/LABA therapies in the next-generation inhalers.
• The major global barrier for the asthma market will be the generic erosion of the leading brands for asthma treatment, such as Advair (fluticasone propionate/salmeterol)and Symbicort (budesonide/formoterol fumarate).
• Companies are trying to penetrate or dominate the asthma market using two main approaches: 1) developing drugs with different delivery devices to capitalize on long-established off-patent therapies; 2) introducing biologics, in particular, interleukin inhibitors, to treat severe uncontrolled asthma.
• The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children.

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/234591

Scope

• Overview of asthma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the asthma therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
• Analysis of the current and future market competition in the global asthma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
• Develop business strategies by understanding the trends shaping and driving the global asthma therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global asthma therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global asthma therapeutics market from 2013-2023.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents

2 Introduction 25

2.1 Catalyst 25

2.2 Related Reports 25

2.3 Upcoming Related Reports 25

3 Disease Overview 26

3.1 Etiology and Pathophysiology 26

3.1.1 Etiology 26

3.1.2 Pathophysiology 28

3.1.3 Prognosis 30

3.1.4 Quality of Life 30

3.2 Symptoms 31

4 Epidemiology 32

4.1 Disease Background 32

4.2 Risk Factors and Comorbidities 33

4.2.1 A family history of asthma is a strong predictor for asthma in children and adults 34

4.2.2 Puberty alters the risk for asthma in boys and girls 35

4.2.3 Maternal smoking during pregnancy greatly increases the risk of childhood asthma 36

4.2.4 Allergens are well-known asthma triggers 37

4.2.5 Common workplace exposures account for up to 11% of asthma cases in adults 38

4.2.6 Urban living conditions, not race, increase the risk of asthma by almost 50% 39

4.2.7 Obesity almost triples the risk of developing asthma 40

4.2.8 Asthmatics are 90% more likely to develop GERD 41

4.2.9 85% of asthmatics have allergic rhinitis 42

4.2.10 Panic disorders are common in asthmatics and severely impact disease control 43

4.2.11 39% of asthmatics are likely to develop depression 44

4.3 Global Trends 44

4.3.1 US 45

4.3.2 France 47

4.3.3 Germany 48

4.3.4 Italy 49

4.3.5 Spain 49

4.3.6 UK 50

4.3.7 Japan 52

4.3.8 Australia 52

4.3.9 China 53

4.3.10 India 54

4.4 Forecast Methodology 55

4.4.1 Sources Used 56

4.4.2 Forecast Assumptions and Methods 69

4.4.3 Sources Not Used 76

4.5 Epidemiology Forecast for Asthma (2013-2023) 77

4.5.1 Lifetime Prevalent Cases of Asthma 77

4.5.2 Age-Specific Lifetime Prevalent Cases of Asthma 79

4.5.3 Sex-Specific Lifetime Prevalent Cases of Asthma 82

4.5.4 Age-Standardized Lifetime Prevalence of Asthma 84

4.5.5 Distribution of Lifetime Prevalent Cases of Asthma by Severity 86

4.6 Discussion 88

4.6.1 Conclusions on Epidemiology Trends 88

4.6.2 Limitations of the Analysis 90

4.6.3 Strengths of the Analysis 91

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Market Research Focused On the PharmaPoint: Asthma - Current and Future Players

"The Report PharmaPoint: Asthma - Current and Future Players provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

GlobalData has released its pharma report, PharmaPoint: Asthma Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies shaping and driving the global Asthma market. The report provides insight into the competitive Asthma landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/225030

Scope

• Investigation of current and future market competition for Asthma
• Competitor assessment
• Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
• Strategic assessment of Asthma sector through market impact analysis, future market scenario and company analysis

Reasons to buy

• Gain a high level view of the trends shaping and driving Asthma market
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market
• Whats the next big thing in the global Asthma market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 6

1.1 List of Tables8

1.2 List of Figures 8

2 Introduction 9

2.1 Catalyst 9

2.2 Related Reports 9

2.3 Upcoming Related Reports 11

3 Market Outlook 12

3.1 Global Markets 12

3.1.1 Forecast 12

3.1.2 Drivers and Barriers - Global Issues 18

4 Current and Future Players 21

4.1 Overview 21

4.2 Trends in Corporate Strategy 23

4.3 Company Profiles 24

4.3.1 GlaxoSmithKline 24

4.3.2 Merck & Co. 27

4.3.3 AstraZeneca/MedImmune 30

4.3.4 Novartis 32

4.3.5 Roche/Genentech 35

4.3.6 Teva 37

4.3.7 Boehringer Ingelheim 40

5 Appendix 43

5.1 Bibliography 43

5.2 Abbreviations 44

5.3 Methodology 46

5.4 Forecasting Methodology 46

5.4.1 Diagnosed Asthma Patients 46

5.4.2 Percent Drug-Treated Patients 47

5.4.3 General Pricing Assumptions 47

5.4.4 Generic Erosion 48

5.5 Physicians and Specialists Included in This Study 49

5.6 About the Authors 52

5.6.1 Author 52

5.6.2 Author/Reviewer 52

5.6.3 Reviewer 53

5.6.4 Global Head of Healthcare 53

5.7 About GlobalData 54

5.8 Disclaimer 54

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Enhancement on PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023

"The Report PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug market will grow at a CAGR of 13.4% over the ten year forecast period, resulting in a market value of $43.4bn by 2023, of which 64% will be attributed to branded drug sales ($27.7bn) and 36% to generic drug sales ($15.7bn). The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

View Report At :http://www.marketresearchreports.biz/analysis/223229

France represents one of the smallest in terms of overall ACS drug sales. Next to the US market, Germany commands the largest global market share for the sale of ACS drugs. Italys contribution to global sales in both 2013 and 2023 falls in the middle of the sales distribution for the 7MM covered in this forecast. Of the 7MMs that were forecast in this report, Spains share of global sales is the smallest for both the 2013 base year and the final forecast year of 2023. Of the markets forecast here, the UK commands the third largest market share in both the 2013 base year and in 2023.

Scope

• Overview of ACS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.
• Analysis of the impact of key events as well the drivers and restraints affecting the 5EU ACS market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return.
• Stay ahead of the competition by understanding the changing competitive landscape for ACS.
• ffectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
• Make more informed business decisions from insightful and in-depth analysis of drug performance.
• Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Download Sample copy of this Report at: http://www.marketresearchreports.biz/sample/sample/223229

Table of Contents

1 Table of Contents

1 Table of Contents 6

1.1 List of Tables 11

1.2 List of Figures 15

2 Introduction 16

2.1 Catalyst 16

2.2 Related Reports 17

2.3 Upcoming Related Reports 19

3 Disease Overview 20

3.1 Etiology and Pathophysiology 21

3.1.1 Etiology 21

3.1.2 Pathophysiology 25

3.1.3 Prognosis 26

3.1.4 Quality of Life 27

3.2 Symptoms 27

4 Disease Management 29

4.1 Treatment Overview 29

4.2 France 34

4.2.1 Diagnosis 34

4.2.2 Clinical Practice 34

4.3 Germany 35

4.3.1 Diagnosis 35

4.3.2 Clinical Practice 35

4.4 Italy 36

4.4.1 Diagnosis 36

4.4.2 Clinical Practice 36

4.5 Spain 37

4.5.1 Diagnosis 37

4.5.2 Clinical Practice 37

4.6 UK 39

4.6.1 Diagnosis 39

4.6.2 Clinical Practice 40

5 Competitive Assessment 42

5.1 Overview 42

5.2 Strategic Competitor Assessment 43

5.3 Product Profiles 48

5.3.1 Fibrinolytic (Thrombolytic) Drugs - Tissue Plasminogen Activator (tPA) 48

5.3.2 Clopidogrel 52

5.3.3 Brilinta (ticagrelor) 56

5.3.4 Effient (prasugrel) 60

5.3.5 Integrilin (eptifibatide) 64

5.3.6 Warfarin 67

5.3.7 Angiomax (bivalirudin) 71

5.3.8 Arixtra (fondaparinux) and the Heparins 74

5.3.9 Statins - HMG-CoA Reductase Inhibitors 78

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreports-biz

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz